Description: Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services. It is focused on oncology, neurology and immunology, and the development of orphan drugs. It has two businesses: Services Business and Co-Development Business. The Services Business is a clinical research business providing services to the pharmaceutical and biotechnology industry. The Co-Development Business is a portfolio of partnerships with pharmaceutical and biotechnology companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including out licensing milestones, as well as sales of the product. It provides clinical development, trial management and pharmacovigilance services to over 100 clients.
Home Page: www.ergomedplc.com
ERGO Technical Analysis
Surrey Research Park
Guildford,
GU2 7HJ
United Kingdom
Phone:
44 1483 503 205
Officers
Name | Title |
---|---|
Dr. Miroslav Reljanovic | Founder & Exec. Chairman |
Mr. Richard T. Barfield | CFO & Exec. Director |
Mr. Michael William Spiteri | Chief Transformation & Technology Officer |
Mr. Shaun Hopgood | Chief Information Officer |
Dr. Michael Forstner | Head of Risk Management & Pharmacoepidemiology |
Ms. Sally Amanuel | Pres of PrimeVigilance |
Dr. Gordana Tonkovic | Pres of Clinical Research |
Ms. Ronel Steyn | Sr. VP of Global Devel. |
Keith Byrne | Sr. Vice-Pres of Capital Markets & Strategy |
Jonathan Curtain | Deputy CFO |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Life Sciences Tools & Services |
GIC Sub-Industry: | Life Sciences Tools & Services |
Forward PE: | 27.5482 |
---|---|
Trailing PE: | 48.2308 |
Price-to-Book MRQ: | 8.6765 |
Price-to-Sales TTM: | 5.0148 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 1371 |